OTCPK:BUENF - Post by User
Post by
minedrilleron Jan 21, 2022 4:35am
276 Views
Post# 34341080
Algernon's Ifenprodil
Algernon's Ifenprodil0% taste loss in pre trial could be another reason for the spongy share price. That just came out of nowhere but two other NDMAs failed in phase 2 suggesting a certain suseptibility of the antagonist. All P2X3s are fairing better with one in late clinical trial. The development nevertheless is something BLU needs to address asap.